The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Recent Advances and Future Directions in Downstream Processing of Therapeutic Antibodies
Abstract
Despite the advent of many new therapies, therapeutic monoclonal antibodies remain a prominent biologics product, with a market value of billions of dollars annually. A variety of downstream processing technological advances have led to a paradigm shift in how therapeutic antibodies are developed and manufactured. A key driver of change has been the increased adoption of single-use technologies for process development and manufacturing. An early-stage developability assessment of potential lead antibodies, using both in silico and high-throughput experimental approaches, is critical to de-risk development and identify molecules amenable to manufacturing. Both statistical and mechanistic modelling approaches are being increasingly applied to downstream process development, allowing for deeper process understanding of chromatographic unit operations. Given the greater adoption of perfusion processes for antibody production, continuous and semi-continuous downstream processes are being increasingly explored as alternatives to batch processes. As part of the Quality by Design (QbD) paradigm, ever more sophisticated process analytical technologies play a key role in understanding antibody product quality in real-time. We should expect that computational prediction and modelling approaches will continue to be advanced and exploited, given the increasing sophistication and robustness of predictive methods compared to the costs, time, and resources required for experimental studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The comprehensive monitoring of all critical quality attributes (CQAs) cannot be achieved with a single analytical technology; instead, an integrated approach combining multiple techniques, sensors and control systems is essential for effective process monitoring and control [20, 26].”
From Current PAT Landscape in the Downstream Processing of Biopharmaceuticals (2025) · cites this paper as [20]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wasalathanthri, D. P., Rehmann, M. S., Song, Y., Gu, Y., Mi, L., Shao, C., Chemmalil, L., Lee, J., Ghose, S., Borys, M. C., et al. (2020) · Biotechnology and Bioengineering · doi:10.1002/bit.27461 · Cited by 177
Multi‐Attribute Method for Quality Control of Therapeutic Proteins
Rogstad, S., Yan, H., Wang, X., Powers, D., Brorson, K., Damdinsuren, B., & Lee, S. (2019) · Analytical Chemistry · doi:10.1021/acs.analchem.9b03808 · Cited by 123
Mahal, H., Branton, H., & Farid, S. S. (2021) · Biotechnology and Bioengineering · doi:10.1002/bit.27774 · Cited by 71
Feidl, F., Garbellini, S., Vogg, S., Sokolov, M., Souquet, J., Broly, H., Butté, A., & Morbidelli, M. (2019) · Biotechnology Progress · doi:10.1002/btpr.2847 · Cited by 59
Patel, B. A., Gospodarek, A., Larkin, M., Kenrick, S. A., Haverick, M. A., Tugcu, N., Brower, M. A., & Richardson, D. D. (2018) · mAbs · doi:10.1080/19420862.2018.1505178 · Cited by 52
Feidl, F., Garbellini, S., Luna, M. F., Vogg, S., Souquet, J., Broly, H., Morbidelli, M., & Butté, A. (2019) · Processes · doi:10.3390/pr7100683 · Cited by 46
Process analytics 4.0: A paradigm shift in rapid analytics for biologics development
Wasalathanthri, D. P., Shah, R., Ding, J., Leone, A., & Li, Z. J. (2021) · Biotechnology Progress · doi:10.1002/btpr.3177 · Cited by 17
Research works printed but not linked: 64
- Vatsa, 2022, In Silico prediction of post-translational modifications in therapeutic antibodies, mAbs, 14, 2023938, 10.1080/19420862.2021.2023938 · DOI
- Liu, 2014, In vitro and in vivo modifications of recombinant and human IgG antibodies, mAbs, 6, 1145, 10.4161/mabs.29883 · DOI · Paper page
- Kerwin, 2020, Framework mutations of the 10-1074 bnAb increase conformational stability, manufacturability, and stability while preserving full neutralization activity, J. Pharm. Sci., 109, 233, 10.1016/j.xphs.2019.07.009 · doi:10.1016/j.xphs.2019.07.009
- Chi, 2021, Pragmatic mAb lead molecule engineering from a developability perspective, Biotechnol. Bioeng., 118, 3733, 10.1002/bit.27802 · DOI
- Seeliger, 2015, Boosting antibody developability through rational sequence optimization, mAbs, 7, 505, 10.1080/19420862.2015.1017695 · DOI
- Robotham, 2019, Detection and quantification of free sulfhydryls in monoclonal antibodies using maleimide labeling and mass spectrometry, mAbs, 11, 757, 10.1080/19420862.2019.1595307 · DOI
- Kim, 2021, Mimicking low pH virus inactivation used in antibody manufacturing proceses: Effect of processing conditions and biophysical properties on antibody aggregation and particle formation, J. Pharm. Sci., 110, 3188, 10.1016/j.xphs.2021.06.002 · DOI
- Vogg, 2020, Understanding mAb aggregation during low pH viral inactivation and subsequent neutralization, Biotechnol. Bioeng., 117, 687, 10.1002/bit.27237 · DOI
- Saleh, 2021, Modeling the impact of amino acid substitution in a monoclonal antibody on cation exchange chromatography, Biotechnol. Bioeng., 118, 2923, 10.1002/bit.27798 · DOI
- Strop, 2012, Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair, J. Mol. Biol., 420, 204, 10.1016/j.jmb.2012.04.020 · DOI
- Kittelmann, 2017, Orientation of monoclonal antibodies in ion-exchange chromatography: A predictive quantitative structure-activity relationship modeling approach, J. Chromatogr. A, 1510, 33, 10.1016/j.chroma.2017.06.047 · doi:10.1016/j.chroma.2017.06.047
- Gudhka, 2021, Identification of preferred multi-modal ligand-binding regions on IgG1 Fc using nuclear magnetic resonance and molecular dynamics simulations, Biotechnol. Bioeng., 118, 809, 10.1002/bit.27611 · DOI
- Lopes, 2015, Single-use in the biopharmaceutical industry: A review of current technology impact, challenges and limitation, Food Bioprod. Process., 93, 98, 10.1016/j.fbp.2013.12.002 · DOI
- Barbaroux, 2020, The green imperative. Part One: Life-cycle assessment and sustainability for single-use technologies in the biopharmaceutical industry, BioProcess Int., 18, 12
- Jacquemart, 2016, A single-use strategy to enable manufacturing of affordable biologics, Comput. Struct. Biotechnol. J., 14, 309, 10.1016/j.csbj.2016.06.007 · DOI
- Hummel, 2019, Modeling the downstream processing of monoclonal antibodies reveals cost advantages for continuous methods for a broad range of manufacturing scales, Biotechnol. J., 14, 1700665, 10.1002/biot.201700665 · DOI
- Menzel, 2021, X-ray sterilization of biopharmaceutical manufacturing equipment—Extractables profile of a film material and copolyester Tritan compared to gamma irradiation, Biotechnol. Prog., 38, e3214, 10.1002/btpr.3214 · doi:10.1002/btpr.3214
- Gaston, 2018, Evaluation of multilayer film stability by Raman spectroscopy after gamma-irradiation sterilization process, Vib. Spectrosc., 96, 52, 10.1016/j.vibspec.2018.03.002 · doi:10.1016/j.vibspec.2018.03.002
- Gaston, 2016, FTIR study of ageing of –irradiated biophamaceutical EVA based film, Polym. Degrad. Stab., 129, 19, 10.1016/j.polymdegradstab.2016.03.040 · doi:10.1016/j.polymdegradstab.2016.03.040
- Madsen, 2010, Effect of sterilization techniques on the physiochemical properties of polysulfone hollow fibers, J. Appl. Polym. Sci., 119, 3429, 10.1002/app.32994 · doi:10.1002/app.32994
- Gao, 2015, Extractables and leachables issues with the application of single-use technology in the biopharmaceutical industry, J. Chem. Technol. Biotechnol., 91, 289, 10.1002/jctb.4824 · DOI
- Matte, A. (2020). Chapter 4—Recent advances in continuous downstream processing of antibodies and related products. Approaches to the Purification, Analysis and Characterization of Antibody-Based Therapeutics, Elsevier.
- Khanal, 2021, Developments and opportunities in continuous biopharmaceutical manufacturing, mAbs, 13, e1903664, 10.1080/19420862.2021.1903664 · DOI
- Kelly, 2014, Understanding and modeling alternating tangential flow filtration for perfusion cell culture, Biotechnol. Prog., 30, 1291, 10.1002/btpr.1953 · DOI
- Madsen, 2022, Single pass tangential flow filtration: Critical operational variables, fouling, and main current applications, Sep. Purif. Technol., 291, 120949, 10.1016/j.seppur.2022.120949 · doi:10.1016/j.seppur.2022.120949
- Tan, 2021, Continuous single pass diafiltration with alternating permeate flow direction for high efficiency buffer exchange, J. Memb. Sci., 619, 118695, 10.1016/j.memsci.2020.118695 · doi:10.1016/j.memsci.2020.118695
- Fedorenko, 2020, Improved protein A resin for antibody capture in a continuous countercurrent tangential chromatography system, Biotechnol. Boeng., 117, 646, 10.1002/bit.27232 · doi:10.1002/bit.27232
- Amritar, 2020, Engineering Staphylococcal Protein A for high-throughput affinity purification of monoclonal antibodies, Biotechnol. Adv., 44, 107632, 10.1016/j.biotechadv.2020.107632 · DOI
- Napoleone, 2021, Fed-batch production assessment of a tetravalent bispecific antibody: A case study on piggyBac stably transfected HEK293 cells, New Biotechnol., 65, 9, 10.1016/j.nbt.2021.07.002 · DOI
- Davis, 2021, Improving mAb capture productivity on batch and continuous processing using nanofiber PrismA adsorbents, J. Biotechnol., 336, 50, 10.1016/j.jbiotec.2021.06.004 · doi:10.1016/j.jbiotec.2021.06.004
- Nadar, 2021, Intensified downstream processing of monoclonal antibodies using membrane technology, Biotechnol. J., 16, 2000309, 10.1002/biot.202000309 · DOI
- Dods, 2015, Fabricating electrospun cellulose nanofiber adsorbents for ion-exchange chromatography, J. Chromatogr. A, 1376, 74, 10.1016/j.chroma.2014.12.010 · doi:10.1016/j.chroma.2014.12.010
- Arnold, 2019, Implementation of fully integrated continuous antibody processing: Effects on productivity and COGm, Biotechnol. J., 14, 1800061, 10.1002/biot.201800061 · DOI
- Gillespie, 2019, Continuous in-line virus inactivation for next generation bioprocessing, Biotechnol. J., 14, 1700718, 10.1002/biot.201700718 · DOI
- Martins, 2020, Truly continuous low pH viral inactivation for biopharmaceutical process integration, Biotechnol. Bioeng., 117, 1406, 10.1002/bit.27292 · DOI
- Kateja, 2021, A novel reactor configuration for continuous virus inactivation, Biochem. Eng. J., 167, 107885, 10.1016/j.bej.2020.107885 · DOI
- Pollard, 2017, Lessons learned in building high-throughput process development capabilities, Eng. Life Sci., 16, 93, 10.1002/elsc.201400254 · DOI
- Kumar, 2014, Design of experiments applications in bioprocessing: Concepts and approaches, Biotechnol. Prog., 30, 86, 10.1002/btpr.1821 · DOI
- Kumar, 2020, Mechanistic modelling of preparative chromatography for biotherapeutics, Ann. Rev. Chem. Biomol. Eng., 11, 235, 10.1146/annurev-chembioeng-102419-125430 · DOI
- Babi, 2022, Opportunities and challenges for model utilization in the biopharmaceutical industry: Current versus future state, Curr. Opin. Chem. Eng., 36, 100813, 10.1016/j.coche.2022.100813 · DOI
- Hanke, 2014, Purifying biopharmaceuticals: Knowledge-based chromatographic process development, Trends Biotechnol., 22, 210, 10.1016/j.tibtech.2014.02.001 · DOI · Paper page
- Benner, 2019, Prediction of lab and manufacturing scale chromatography using min-columns and mechanistic modelling, J. Chromatogr. A, 1593, 54, 10.1016/j.chroma.2019.01.063 · DOI
- Schmölder, J., and Kaspereit, M. (2020). A modular framework for the modelling and optimization of advanced chromatographic processes. Processes, 8. · DOI
- Leweke, 2018, Chromatography analysis and design toolkit (CADET), Comput. Chem. Eng., 113, 274, 10.1016/j.compchemeng.2018.02.025 · DOI
- Rischawy, 2019, Good modelling practise for industrial chromatography: Mechanistic modelling of ion exchange chromatography of a bispecific antibody, Comput. Chem. Eng., 130, 106532, 10.1016/j.compchemeng.2019.106532 · DOI
- Briskot, 2019, Prediction uncertainty assessment of chromatography models using Bayesian inference, J. Chromatogr. A, 1587, 101, 10.1016/j.chroma.2018.11.076 · DOI
- Shekhawat, 2018, Design of experiments applications in bioprocessing: Chromatography process development using split design of experiments, Biotechnol. Prog., 35, e2730, 10.1002/btpr.2730 · doi:10.1002/btpr.2730
- Shekhawat, 2016, Enablers for QbD implementation: Mechanistic modeling for ion-exchange membrane chromatography, J. Memb. Sci., 500, 86, 10.1016/j.memsci.2015.10.063 · doi:10.1016/j.memsci.2015.10.063
- Graalfs, 2021, Mechanistic modelling of ligand density variations on anion exchange chromatography, J. Sep. Sci., 44, 805, 10.1002/jssc.202001077 · DOI
- Gerzon, 2021, Process analytical technologies—Advances in bioprocess integration and future perspectives, J. Pharm. Biomed. Anal., 207, 114379, 10.1016/j.jpba.2021.114379 · DOI · Paper page
- Maruthamuthu, 2020, Process analytical technologies and data analytics for the manufacture of monoclonal antibodies, Trends Biotechnol., 38, 1169, 10.1016/j.tibtech.2020.07.004 · DOI
- São Pedro, M.N., Klijn, M.E., Eppink, M.H.M., and Ottens, M. (2021). Process analytical technique (PAT) miniaturization for monoclonal antibody aggregate detection in continuous downstream processing. J. Chem. Technol. Biotechnol. · DOI
- Jiang, 2017, Opportunities and challenges of real-time release testing in biopharmaceutical manufacturing, Biotechnol. Bioeng., 114, 2445, 10.1002/bit.26383 · DOI · Paper page
- Brestrich, 2018, Selective protein quantification for preparative chromatography using variable pathelength UV/Vis spectroscopy and partial least squares regression, Chem. Engin. Sci., 176, 157, 10.1016/j.ces.2017.10.030 · DOI
- Ly, T.T., Ruan, Y., Du, B., Jia, P., and Zhang, H. (2021). Fibre-optic surface plasmon resonance biosensor for monoclonal antibody titer quantification. Biosensors, 11. · DOI
- Rolinger, 2021, Comparison of UV- and Raman-based monitoring of the Protein A load phase and evaluation of data fusion by PLS models and CNNs, Biotechnol. Bioeng., 118, 4255, 10.1002/bit.27894 · DOI · Paper page
- Yilmaz, 2019, Application of Raman spectroscopy in monoclonal antibody producing continuous systems for downstream process intensification, Biotechnol. Prog., 36, e2947, 10.1002/btpr.2947 · DOI · Paper page
- Tiwari, 2018, Use of HPLC as an enabler of process analytical technology in process chromatography, Anal. Chem., 90, 7824, 10.1021/acs.analchem.8b00897 · DOI
- Chemmalil, 2020, Online/at-line measurement, analysis and control of product titre and critical product quality attributes (CQAs) during process development, Biotechnol. Bioeng., 117, 3757, 10.1002/bit.27531 · DOI
- Gillespie, 2021, Systematic assessment of process analytical technologies for biologics, Biotechnol. Bioeng., 119, 423, 10.1002/bit.27990 · DOI
- West, 2021, Process analytical technology for on-line monitoring of quality attributes during single-use ultrafiltration/diafiltration, Biotechnol. Bioeng., 118, 2293, 10.1002/bit.27741 · DOI
- Liu, 2022, A fully integrated online platform for real-time monitoring of multiple product quality attributes in biopharmaceutical processes for monoclonal antibody therapeutics, J. Pharm. Sci., 111, 358, 10.1016/j.xphs.2021.09.011 · DOI · Paper page
- Rogers, 2018, A view on the importance of “multi attribute method” for measuring purity of biopharmaceuticals and improving overall control strategy, AAPS J., 20, 7, 10.1208/s12248-017-0168-3 · DOI
- Jakes, 2021, Rapid analysis of biotherapeutics using Protein A chromatography coupled to Orbitrap mass spectrometry, Anal. Chem., 93, 13505, 10.1021/acs.analchem.1c02365 · DOI
Cited by
Bioprocessing 4.0 in Biomanufacturing: Paving the Way for Sustainable Bioeconomy
Pandey, K., Pandey, M., Kumar, V., Aggarwal, U., & Singhal, B. (2024) · Systems Microbiology and Biomanufacturing · doi:10.1007/s43393-023-00206-y · Cited by 58
Current PAT Landscape in the Downstream Processing of Biopharmaceuticals
Sathiyapriyan, P., Mukherjee, S., Vogel, T., Essen, L., Boerema, D., Vey, M., & Kalina, U. (2025) · Analytical Science Advances · doi:10.1002/ansa.70013 · Cited by 45
Tran, T., Martinsson, E., Gustavsson, R., Tronarp, O., Nilsson, M., Hansson, K. R., Lundström, I., Mandenius, C.-F., & Aili, D. (2022) · Analytical Methods · doi:10.1039/d2ay01567f · Cited by 10
Westwood, F., Ponstingl, M., & Dickens, J. E. (2024) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2024.115965 · Cited by 4
Metadata
- Authors
- Matte, A.
- Affiliations
- Downstream Processing Team, Bioprocess Engineering Department, Human Health Therapeutics Research Center, National Research Council Canada, 6100 Royalmount Avenue, Montreal, QC H4P 2R2, Canada
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-08-04
- Volume
- 23
- Issue
- 15
- Pages
- 8663
- ISSN
- 1422-0067
- PMC
- PMC9369434
- Cited by
- 36
- References
- 7
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recent Advances and Future Directions in Downstream Processing of Therapeutic Antibodies. https://app.cochat.ai/papers/10.3390/ijms23158663
- The paper
- Matte, A. (2022). Recent Advances and Future Directions in Downstream Processing of Therapeutic Antibodies. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms23158663
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
